JP2005528348A - Ppar活性を変調するチアゾールおよびオキサゾール誘導体 - Google Patents

Ppar活性を変調するチアゾールおよびオキサゾール誘導体 Download PDF

Info

Publication number
JP2005528348A
JP2005528348A JP2003572567A JP2003572567A JP2005528348A JP 2005528348 A JP2005528348 A JP 2005528348A JP 2003572567 A JP2003572567 A JP 2003572567A JP 2003572567 A JP2003572567 A JP 2003572567A JP 2005528348 A JP2005528348 A JP 2005528348A
Authority
JP
Japan
Prior art keywords
methyl
phenyl
compound
trifluoromethyl
thiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003572567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528348A5 (https=
Inventor
シュー−ミン・チェン
ノエ・ワーノ・エラスガ
ゲアリ・フレデリック・フィルゼン
アンドルー・ジョージ・ガイアー
チタセ・リー
ブハラト・カリダス・トリヴェディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2005528348A publication Critical patent/JP2005528348A/ja
Publication of JP2005528348A5 publication Critical patent/JP2005528348A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2003572567A 2002-03-07 2003-02-24 Ppar活性を変調するチアゾールおよびオキサゾール誘導体 Abandoned JP2005528348A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (en) 2002-03-07 2003-02-24 Thiazole and oxazole derivatives which modulate ppar activity

Publications (2)

Publication Number Publication Date
JP2005528348A true JP2005528348A (ja) 2005-09-22
JP2005528348A5 JP2005528348A5 (https=) 2006-04-13

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572567A Abandoned JP2005528348A (ja) 2002-03-07 2003-02-24 Ppar活性を変調するチアゾールおよびオキサゾール誘導体

Country Status (29)

Country Link
US (1) US20030207924A1 (https=)
EP (1) EP1482935B1 (https=)
JP (1) JP2005528348A (https=)
KR (1) KR20040091693A (https=)
AP (1) AP2004003124A0 (https=)
AR (1) AR038881A1 (https=)
AT (1) ATE405260T1 (https=)
AU (1) AU2003206059A1 (https=)
BR (1) BR0308277A (https=)
CA (1) CA2478520A1 (https=)
CO (1) CO5601012A2 (https=)
DE (1) DE60323060D1 (https=)
EA (1) EA200400943A1 (https=)
EC (1) ECSP045285A (https=)
ES (1) ES2310650T3 (https=)
HN (1) HN2003000090A (https=)
IS (1) IS7377A (https=)
MA (1) MA27181A1 (https=)
MX (1) MXPA04007564A (https=)
NO (1) NO20044242L (https=)
OA (1) OA12780A (https=)
PA (1) PA8567801A1 (https=)
PE (1) PE20030989A1 (https=)
PL (1) PL372969A1 (https=)
TN (1) TNSN04168A1 (https=)
TW (1) TW200305403A (https=)
UY (1) UY27695A1 (https=)
WO (1) WO2003074050A1 (https=)
ZA (1) ZA200406068B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
WO2007102515A1 (ja) * 2006-03-07 2007-09-13 Astellas Pharma Inc. フェニルチアゾール誘導体
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
JP2013525267A (ja) * 2010-02-25 2013-06-20 エスエヌユー アール&ディービー ファウンデーション ペルオキシソーム増殖剤活性化受容体リガンドのセレナゾール誘導体、その製造方法及びその化合物の用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
CN101193876B (zh) * 2005-05-07 2011-05-11 财团法人首尔大学校产学协力财团 制备PPARδ的配体的方法和用于制备该配体的中间化合物
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2002233271A1 (en) * 2000-12-20 2002-07-01 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
HRP20031002A2 (en) * 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006528987A (ja) * 2003-05-19 2006-12-28 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions
WO2007102515A1 (ja) * 2006-03-07 2007-09-13 Astellas Pharma Inc. フェニルチアゾール誘導体
JP2013525267A (ja) * 2010-02-25 2013-06-20 エスエヌユー アール&ディービー ファウンデーション ペルオキシソーム増殖剤活性化受容体リガンドのセレナゾール誘導体、その製造方法及びその化合物の用途

Also Published As

Publication number Publication date
EP1482935B1 (en) 2008-08-20
UY27695A1 (es) 2003-10-31
AP2004003124A0 (en) 2004-09-30
NO20044242L (no) 2004-10-06
EP1482935A1 (en) 2004-12-08
ECSP045285A (es) 2004-10-26
MA27181A1 (fr) 2005-01-03
ATE405260T1 (de) 2008-09-15
TW200305403A (en) 2003-11-01
DE60323060D1 (de) 2008-10-02
US20030207924A1 (en) 2003-11-06
AU2003206059A1 (en) 2003-09-16
CA2478520A1 (en) 2003-09-12
WO2003074050A1 (en) 2003-09-12
PA8567801A1 (es) 2003-11-12
IS7377A (is) 2004-07-29
HN2003000090A (es) 2004-05-05
PL372969A1 (en) 2005-08-08
CO5601012A2 (es) 2006-01-31
OA12780A (en) 2006-07-07
ES2310650T3 (es) 2009-01-16
PE20030989A1 (es) 2003-11-29
BR0308277A (pt) 2004-12-28
TNSN04168A1 (fr) 2007-03-12
MXPA04007564A (es) 2004-11-10
KR20040091693A (ko) 2004-10-28
EA200400943A1 (ru) 2005-02-24
AR038881A1 (es) 2005-02-02
ZA200406068B (en) 2005-09-06

Similar Documents

Publication Publication Date Title
JP2005528348A (ja) Ppar活性を変調するチアゾールおよびオキサゾール誘導体
JP3490704B2 (ja) チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用
US6833380B2 (en) Compounds that modulate PPAR activity and methods of preparation
JP2005527509A (ja) Ppar活性を調節する、置換チアゾールおよびオキサゾール
CZ20031737A3 (cs) Thiazolové deriváty
RS82904A (sr) Jedinjenja koja moduliraju delovanje ppar i postupci za njihovo dobijanje
SK1962001A3 (en) Substituted oxazoles and thiazoles derivatives as hppar gamma and hppar alpha activators
MXPA04007177A (es) Alimentacion para animales baja en fosforo y metodo para hacer la misma.
MXPA01001419A (en) SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060224

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20080903